The DrugBank accession number for rimegepant is DB15406. DrugBank is a comprehensive database of drug-related information, including chemical and pharmacological data.
What is Rimegepant?
Rimegepant is an oral medication approved for the acute treatment of migraine with or without aura in adults. It belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists [1].
How does Rimegepant work?
Rimegepant works by blocking the activity of CGRP, a neuropeptide that is thought to play a role in migraine pathophysiology. By inhibiting CGRP, rimegepant helps to reduce inflammation and vasodilation in the brain, which can alleviate migraine pain [1].
When did Rimegepant gain FDA approval?
The U.S. Food and Drug Administration (FDA) approved rimegepant for the acute treatment of migraine in December 2019 [2].
What are the approved uses for Rimegepant?
In addition to acute migraine treatment, rimegepant is also approved for the preventive treatment of episodic migraine in adults, with the first dose taken on a given day used to treat a current migraine, and subsequent doses taken every other day as needed for prevention [3].
What is the difference between Nurtec ODT and Qulipta?
Rimegepant is marketed under two brand names: Nurtec ODT, for acute and preventive migraine treatment, and Qulipta, specifically for the preventive treatment of episodic migraine. While both contain the same active ingredient, their approved indications and dosing regimens differ [3].
How does Rimegepant compare to other migraine treatments?
Rimegepant offers an alternative to traditional acute migraine treatments like triptans and ergotamines, and also provides a preventive option. It is part of a new class of CGRP inhibitors that target the underlying mechanisms of migraine [1]. Other CGRP antagonists include gepants like ubrogepant, as well as injectable monoclonal antibodies [4].
What are the potential side effects of Rimegepant?
Common side effects associated with rimegepant include nausea and fatigue [1].
Does Rimegepant have patent protection?
Drug patents are crucial for pharmaceutical innovation. Information on the patent status of rimegepant, including expiry dates and any patent challenges, can be found through resources like DrugPatentWatch.com [5].
Who manufactures Rimegepant?
Rimegepant is manufactured by Biohaven Pharmaceuticals [2].
What is the typical dosage and administration of Rimegepant?
For acute migraine treatment, the recommended dose of Nurtec ODT is 75 mg taken orally as needed. For preventive treatment of episodic migraine, Qulipta is typically taken every other day at a dose of 62.5 mg [3].
Sources:
1. https://go.drugbank.com/drugs/DB15406
2. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-certifications
3. https://www.fda.gov/drugs/drug-label-internet/nurtec-odt-qulipta
4. https://www.drugpatentwatch.com/blog/what-are-cgrp-inhibitors
5. https://www.drugpatentwatch.com/